Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 8
Submit an article Journal homepage
697
Views
45
CrossRef citations to date
0
Altmetric
Original Articles: Research

Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma

Dan T. VoglAbramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA; Correspondence[email protected]
,
Thomas G. MartinAdult Leukemia and Bone Marrow Transplantation Program, University of California San Francisco, San Francisco, CA, USA;
,
Ravi VijBone Marrow Transplantation and Leukemia Section, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA;
,
Parameswaran HariAdult Blood and Marrow Transplant Program, Medical College of Wisconsin, Milwaukee, WI, USA;
,
Joseph R. MikhaelDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA;
,
David SiegelJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA;
,
Ka Lung WuDepartment of Hematology, ZNA Stuivenberg, Antwerp, Belgium;
,
Michel DelforgeDepartment of Hematology, University Hospital Leuven, Leuven, Belgium;
&
Cristina GasparettoDivision of Medicine–Cell Therapy and Hematologica, Duke University Medical Center, Durham, NC, USA
 show all
Pages 1872-1879 | Received 12 Aug 2016, Accepted 18 Nov 2016, Published online: 31 Jan 2017

Citations (45)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mothana K. Al-Omari, Mai Elaarag, Raed M. Al-Zoubi, Ahmad R. Al-Qudimat, Ayman A. Zarour, Enas A. Al-Hurani, Zainab E. Fares, Leena M. Alkharraz, Mohanad Shkoor, Abdulilah D. Bani-Yaseen, Omar M. Aboumarzouk, Aksam Yassin & Abdulla A. Al-Ansari. (2023) Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope. Journal of Enzyme Inhibition and Medicinal Chemistry 38:1.
Read now
Giorgia Gazzaroli, Andrea Angeli, Arianna Giacomini & Roberto Ronca. (2023) Proteasome inhibitors as anticancer agents. Expert Opinion on Therapeutic Patents 0:0, pages 1-22.
Read now

Articles from other publishers (43)

David Kegyes, Diana Gulei, Rares Drula, Diana Cenariu, Bogdan Tigu, Delia Dima, Alina Tanase, Sorina Badelita, Anca-Dana Buzoianu, Stefan Ciurea, Gabriel Ghiaur, Evangelos Terpos, Aaron Ciechanover, Hermann Einsele & Ciprian Tomuleasa. (2023) Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Reviews 61, pages 101100.
Crossref
Krishnendu Sinha, Jyotirmoy Ghosh & Parames Chandra Sil. (2022) Machine Learning in Drug Metabolism Study. Current Drug Metabolism 23:13, pages 1012-1026.
Crossref
Nataša Pavlović & Femke Heindryckx. (2021) Targeting ER stress in the hepatic tumor microenvironment. The FEBS Journal 289:22, pages 7163-7176.
Crossref
Jin-Taek Hwang, Ahyoung Lee & Changwon Kho. (2022) Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases. International Journal of Molecular Sciences 23:9, pages 5053.
Crossref
Conor Horgan & Timothy P. O’Sullivan. (2022) Recent Developments in the Practical Application of Novel Carboxylic Acid Bioisosteres. Current Medicinal Chemistry 29:13, pages 2203-2234.
Crossref
Anna-Katharina Holzer, Ilinca Suciu, Christiaan Karreman, Thomas Goj & Marcel Leist. (2022) Specific Attenuation of Purinergic Signaling during Bortezomib-Induced Peripheral Neuropathy In Vitro. International Journal of Molecular Sciences 23:7, pages 3734.
Crossref
Carlota Leonardo-Sousa, Andreia Neves Carvalho, Romina A. Guedes, Pedro M. P. Fernandes, Natália Aniceto, Jorge A. R. Salvador, Maria João Gama & Rita C. Guedes. (2022) Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance. Molecules 27:7, pages 2201.
Crossref
Fatima Abi-Ghaida. 2022. Fundamentals and Applications of Boron Chemistry. Fundamentals and Applications of Boron Chemistry 321 410 .
Suzane Quintana Gomes, Guilherme Martins Silva, Mariana Pegrucci Barcelos, Lorane Izabel da Silva Hage-Melim & Carlos Henrique Tomich de Paula da Silva. 2022. Research Topics in Bioactivity, Environment and Energy. Research Topics in Bioactivity, Environment and Energy 545 567 .
Jianhao Liu, Ruogang Zhao, Xiaowen Jiang, Zhaohuan Li & Bo Zhang. (2021) Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations. Biomolecules 12:1, pages 51.
Crossref
Chun-fung Sin & Pui-hei Marcus Man. (2021) The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia. Frontiers in Oncology 11.
Crossref
Ruqaia Abbas & Sarit Larisch. (2021) Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System. Cells 10:12, pages 3465.
Crossref
Anmol Sharma, Heena Khan, Thakur Singh, Amarjot Grewal, Agnieszka Najda, Małgorzata Kawecka-Radomska, Mohamed Kamel, Ahmed Altyar & Mohamed Abdel-Daim. (2021) Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling. International Journal of Molecular Sciences 22:21, pages 11971.
Crossref
Wenbo Ming, Harjeet S. Soor, Xiaocui Liu, Alina Trofimova, Andrei K. Yudin & Todd B. Marder. (2021) α-Aminoboronates: recent advances in their preparation and synthetic applications. Chemical Society Reviews 50:21, pages 12151-12188.
Crossref
Ashley Y. Choi, Miriam Manook, Danae Olaso, Brian Ezekian, Jaeberm Park, Kyle Freischlag, Annette Jackson, Stuart Knechtle & Jean Kwun. (2021) Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. Frontiers in Immunology 12.
Crossref
Lei Zhong, Yueshan Li, Liang Xiong, Wenjing Wang, Ming Wu, Ting Yuan, Wei Yang, Chenyu Tian, Zhuang Miao, Tianqi Wang & Shengyong Yang. (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy 6:1.
Crossref
Stefano Fogli, Sara Galimberti, Veronica Gori, Marzia Del Re & Romano Danesi. (2021) Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. Pharmacological Research 167, pages 105537.
Crossref
Andrej Šterman, Janez Košmrlj, Nina Žigart, Stanislav Gobec, Izidor Sosič & Zdenko Časar. (2021) Catalytic Approach to Diverse α‐Aminoboronic Acid Derivatives by Iridium‐Catalyzed Hydrogenation of Trifluoroborate‐Iminiums. Advanced Synthesis & Catalysis 363:9, pages 2396-2402.
Crossref
Rao Song, Wenliang Qiao, Jun He, Jiasheng Huang, Youfu Luo & Tao Yang. (2021) Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities. Journal of Medicinal Chemistry 64:6, pages 2851-2877.
Crossref
Niels van Nieuwenhuijzen, Rowan Frunt, Anne M. May & Monique C. Minnema. (2021) Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis. Blood Cancer Journal 11:3.
Crossref
Xiuzhen Zhang, Tong Meng, Shuaishuai Cui, Ling Feng, Dongwu Liu, Qiuxiang Pang & Ping Wang. (2021) Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment. Frontiers in Oncology 10.
Crossref
Iván R Vega-Valdez, Rosalez Melvin N., Santiago-Quintana José M., Farfán-García Eunice D. & Soriano-Ursúa Marvin A.. (2021) Docking Simulations Exhibit Bortezomib and other Boron-containing Peptidomimetics as Potential Inhibitors of SARS-CoV-2 Main Protease. Current Chemical Biology 14:4, pages 279-288.
Crossref
M. Michael Dcona, Koushambi Mitra & Matthew C. T. Hartman. (2020) Photocontrolled activation of small molecule cancer therapeutics. RSC Medicinal Chemistry 11:9, pages 982-1002.
Crossref
G.R. Tundo, D. Sbardella, A.M. Santoro, A. Coletta, F. Oddone, G. Grasso, D. Milardi, P.M. Lacal, S. Marini, R. Purrello, G. Graziani & M. Coletta. (2020) The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacology & Therapeutics 213, pages 107579.
Crossref
Jessica Plescia & Nicolas Moitessier. (2020) Design and discovery of boronic acid drugs. European Journal of Medicinal Chemistry 195, pages 112270.
Crossref
Jessica L. Rausch, Areej A. Ali, Donna M. Lee, Yemarshet K. Gebreyohannes, Keith R. Mehalek, Aya Agha, Sneha S. Patil, Yanis Tolstov, Jasmien Wellens, Harbir S. Dhillon, Kathleen R. Makielski, Maria Debiec-Rychter, Patrick Schöffski, Agnieszka Wozniak & Anette Duensing. (2020) Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. Scientific Reports 10:1.
Crossref
Silpa Narayanan, Chao-Yun Cai, Yehuda G. Assaraf, Hui-Qin Guo, Qingbin Cui, Liuya Wei, Juan-Juan Huang, Charles R. AshbyJrJr & Zhe-Sheng Chen. (2020) Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resistance Updates 48, pages 100663.
Crossref
Zvi RappoportCory Williams, Mario Luis, Ivan Lopez & Adiel Coca. 2010. Patai's Chemistry of Functional Groups. Patai's Chemistry of Functional Groups 1 21 .
Anthony J. O’Donoghue, Betsaida Bibo-Verdugo, Yukiko Miyamoto, Steven C Wang, Justin Z. Yang, Douglas E. Zuill, Shoun Matsuka, Zhenze Jiang, Jehad Almaliti, Conor R. Caffrey, William H. Gerwick & Lars Eckmann. (2019) 20S Proteasome as a Drug Target in Trichomonas vaginalis. Antimicrobial Agents and Chemotherapy 63:11.
Crossref
Karim Hnia, Tim Clausen & Christel Moog-Lutz. (2019) Shaping Striated Muscles with Ubiquitin Proteasome System in Health and Disease. Trends in Molecular Medicine 25:9, pages 760-774.
Crossref
Sheng Wang, Dexi Zhou, Zhenyu Xu, Jing Song, Xueyi Qian, Xiongwen Lv & Jiajie Luan. (2019) Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. Current Drug Targets 20:11, pages 1180-1202.
Crossref
S. V. Semochkin. (2019) New proteasome inhibitors in the management of multiple myeloma. Oncohematology 14:2, pages 29-40.
Crossref
Min Jae Lee, Deepak Bhattarai, Jisu Yoo, Zach Miller, Ji Eun Park, Sukyeong Lee, Wooin Lee, James J. Driscoll & Kyung Bo Kim. (2019) Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib. Journal of Medicinal Chemistry 62:9, pages 4444-4455.
Crossref
Andrej Besse, Lenka Besse, Marianne Kraus, Max Mendez-Lopez, Jürgen Bader, Bo-Tao Xin, Gerjan de Bruin, Elmer Maurits, Herman S. Overkleeft & Christoph Driessen. (2019) Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. Cell Chemical Biology 26:3, pages 340-351.e3.
Crossref
Dávid Vrábel, Luděk Pour & Sabina Ševčíková. (2019) The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Reviews 34, pages 56-66.
Crossref
Peter Bloomingdale & Donald E. Mager. (2019) Machine Learning Models for the Prediction of Chemotherapy-Induced Peripheral Neuropathy. Pharmaceutical Research 36:2.
Crossref
Kiyoshi Okazuka & Tadao Ishida. (2018) Proteasome inhibitors for multiple myeloma. Japanese Journal of Clinical Oncology 48:9, pages 785-793.
Crossref
Hanley N. Abramson. (2018) The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets. Clinical Lymphoma Myeloma and Leukemia 18:9, pages 611-627.
Crossref
Ji Eun Park, Zachary Miller, Yearin Jun, Wooin Lee & Kyung Bo Kim. (2018) Next-generation proteasome inhibitors for cancer therapy. Translational Research 198, pages 1-16.
Crossref
Wenjie Zhang, Heyuan Bai, Liqiang Han, Han Zhang, Bo Xu, Jingrong Cui, Xin Wang, Zemei Ge & Runtao Li. (2018) Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors. Bioorganic & Medicinal Chemistry Letters 28:14, pages 2459-2464.
Crossref
Ishita Gupta, Kanika Singh, Nishant K. Varshney & Sameena Khan. (2018) Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis. Frontiers in Cell and Developmental Biology 6.
Crossref
Roberta Ettari, Maria Zappalà, Silvana Grasso, Caterina Musolino, Vanessa Innao & Alessandro Allegra. (2018) Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. Pharmacology & Therapeutics 182, pages 176-192.
Crossref
Blake E. Daniels & Craig E. Stivala. (2018) A solid-phase approach for the synthesis of α-aminoboronic acid peptides. RSC Advances 8:6, pages 3343-3347.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.